These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
544 related articles for article (PubMed ID: 30826508)
1. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
3. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
5. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
6. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
7. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. Ahmed MF; Santali EY; El-Haggar R J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069 [TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents. Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750 [TBL] [Abstract][Full Text] [Related]
10. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors. Sun W; Hu S; Fang S; Yan H Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives. El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653 [TBL] [Abstract][Full Text] [Related]
16. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
17. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study. El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase. Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors. Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467 [TBL] [Abstract][Full Text] [Related]
20. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]